---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-202760"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:39:41.913007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M

## Summary
- Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.
- Up to $5.7B in total milestone payments plus tiered royalties (high single to low double-digits) across up to three programs.
- Novartis gets exclusive license to one undisclosed discovery target and options on two additional preclinical I&I programs.
- Second collaboration with Novartis; first (VAV1/MRT-6160) was announced Oct 2024.
- Extended cash runway accelerates preclinical and clinical-stage immunology pipeline; Phase 2 readouts expected for MRT-8102, MRT-6160, MRT-2359.

## SEC filing metadata
- accession: 0001193125-25-202760
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/0001193125-25-202760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/glue-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-202760
- JSON: https://secwatch.observer/filing/0001193125-25-202760.json
- Plain text: https://secwatch.observer/filing/0001193125-25-202760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.